Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
LAMIRA®, an eFlow® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union
PARI's optimized Investigational eFlow® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.
